2. Induced Disease Models Products Immunology/Inflammation Anti-infection
  3. Immunology and Inflammatory Disease Models Digestive System Disease Models COX Bacterial Influenza Virus Antibiotic
  4. Gastrointestinal Inflammation and Ulcer Models Gastrointestinal Disease Models
  5. Gastric Ulcer Models
  6. Indomethacin sodium hydrate

Indomethacin sodium hydrate  (Synonyms: Indometacin sodium hydrate)

Cat. No.: HY-14397A Purity: 99.85%
COA
SDS
Handling Instructions Technical Support

Indomethacin (Indometacin) sodium hydrateis a orally active and BBB-permeable COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin sodium hydrateis has anticancer activity and anti-infective activity. Indomethacin sodium hydrateis can be used for cancer, inflammation and viral infection research.

For research use only. We do not sell to patients.

CAS No. : 74252-25-8

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
500 mg In-stock
1 g In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 76 publication(s) in Google Scholar

Other Forms of Indomethacin sodium hydrate:

Indomethacin sodium hydrate Related Antibodies

Top Publications Citing Use of Products

76 Publications Citing Use of MCE Indomethacin sodium hydrate

ELISA
WB
IF
Cell Proliferation/Viability Assay
In Vivo Efficacy Study

    Indomethacin sodium hydrate purchased from MedChemExpress. Usage Cited in: Hepatology. 2023 Feb 1;77(2):456-465.  [Abstract]

    WT BmEos was treated with IL-33 (20 ng/ml) in the presence or absence of indomethacin (50 μM) for 24 h. Protein levels of IL-4 and IL-13 in the supernatants were measured by ELISA.

    Indomethacin sodium hydrate purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2021 Oct;11(10):e548.  [Abstract]

    ITGAV, ITGB3, p-FAK, FAK, p-PI3K, PI3K, p-AKT, AKT, p-GSK3β, and GSK3β protein levels were assessed in KYSE30 cells by Western blotting after treatment with DMSO or 200 µM Indomethacin (0–96 h).

    Indomethacin sodium hydrate purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2021 Oct;11(10):e548.  [Abstract]

    HEK-293T cells were co-transfected with FLAG-ITGAV and HA-ubiquitin plasmids, pre-treated with MG132 for 12 h, and then incubated with indomethacin (200 µM) for 2 days.

    Indomethacin sodium hydrate purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2021 Oct;11(10):e548.  [Abstract]

    KYSE30 and KYSE510 cells were treated with DMSO or Indomethacin for 24 h, followed by the detection of ITGAV protein levels using immunofluorescence.

    Indomethacin sodium hydrate purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2021 Oct;11(10):e548.  [Abstract]

    ESCC cells were treated with DMSO or different concentrations of Indomethacin for various times (24, 48, or 96 h). Cell growth inhibition was detected by MTT assay.

    Indomethacin sodium hydrate purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2021 Oct;11(10):e548.  [Abstract]

    PDX tumour size was plotted over 41 days (LEG74, n = 8/group), 26 days (LEG92, n = 12/group), or 13 days (LEG84, n = 10/group) to assess the effect of Indomethacin. Vehicle or indomethacin (1 or 4 mg/kg) was administered intra-gastrically. Tumour volumes were measured twice per week.

    View All COX Isoform Specific Products:

    View All Isoforms
    COX COX-1 COX-2 COX-3

    View All Antibiotic Isoform Specific Products:

    View All Isoforms
    Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Indomethacin (Indometacin) sodium hydrateis a orally active and BBB-permeable COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin sodium hydrateis has anticancer activity and anti-infective activity. Indomethacin sodium hydrateis can be used for cancer, inflammation and viral infection research[1][2][3].

    In Vitro

    Indomethacin (Indometacin) sodium hydrateis (0-150 μM; 24 hours; 3LL-D122 cells) has anticancer activity in vitro[2].
    Indomethacin (Indometacin) sodium hydrateis (0-1000 μM) protects the host cells from damage caused by the virus through activates PKR, resulting in elF2α phosphorylation, and in turn shutting of translation of viral protein and inhibiting replication of the virus (IC50=2 μM)[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Indomethacin sodium hydrate Related Antibodies

    Cell Viability Assay[2]

    Cell Line: 3LL-D122 cells (highly metastatic variant of mouse LLcarcinoma cells)
    Concentration: 0, 20, 50, 100 and 150μM
    Incubation Time: 24 hours
    Result: Inhibited cell viability at 20 mM, with 50% inhibition at 60 mM.

    Cell Cycle Analysis[2]

    Cell Line: 3LL-D122 cells (highly metastatic variant of mouse LLcarcinoma cells)
    Concentration: 0, 30 and 80μM
    Incubation Time: 24 hours
    Result: Decreased in the percentage of cells at the G2/M phase and increased in the percentage of cells at G1 phase.
    In Vivo

    Note:
    Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

    Indomethacin sodium hydrate can be used to create gastric ulcer models. After oral administration, the drug is absorbed rapidly and completely, although there are interindividual and intraindividual variations. The plasma peak concentration of 2-3 μg/mL is typically reached within 1-2 hours. However, coadministration with food reduces and delays the peak concentration without affecting the total absorption. At therapeutic concentrations, 90% of Indomethacin is bound to albumin in the plasma[4].

    Induction of gastric ulceration[5][6]
    Background
    Indomethacin can cause gastric ulceration by various mechanisms, including injury through inhibition of prostaglandin (PG) synthesis, reduction in local blood flow, regional irritation, and inhibition of tissue regeneration.
    Specific Modeling Methods
    Rat: albino Sprague-Dawley • male • adult (period: 2 weeks)
    Administration: 100 mg/kg • p.o. • single dose
    Note
    (1) All animals fasted 24 h before drug administration.
    (2) Indomethacin were dissolved in saline with 5% NaOH.
    Modeling Indicators
    Gastric tissue macroscopic alterations: Showed prominent mucosal folds and severe erosion, pronounced ulceration and bleeding foci in the gastric mucosa.
    Histopathological changes: Showed severe erosion of the mucosa, reaching down to the lamina muscularis; observed hemorrhagic infiltration, edema in the submucosa, and severe hyperemia of the vessels.
    Molecular changes: Showed intense Tnf-α expression.
    Biochemical changes: Increased MDA, TOS levels, reduced TAS levels, CAT and GPx activities and GSH levels.
    Correlated Product(s): Indomethacin sodium hydrate (HY-14397A)
    Opposite Product(s): Carnosic acid (HY-N0644)

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Male Sprague-Dawley rats[1]
    Dosage: 0.01-10 mg/kg
    Administration: Oral administration; for 3 hours
    Result: Inhibited the carrageenan-induced rat paw oedema (ED50=2.0 mg/kg) and hyperalgesia (ED50=1.5 mg/kg) in a dose-dependent manner.
    Animal Model: Male C57BL/6J mice[2]
    Dosage: 10 mg/mL
    Administration: Oral administration; daily, for 29 days
    Result: Delayed the onset of tumor growth and the initial growth rate of the footpad tumors.
    Clinical Trial
    Molecular Weight

    433.82

    Formula

    C19H21ClNNaO7
    CAS No.
    Appearance

    Solid

    Color

    Light yellow to yellow

    SMILES

    O=C(O[Na])CC1=C(C)N(C(C2=CC=C(Cl)C=C2)=O)C3=C1C=C(OC)C=C3.O.O.O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, protect from light, stored under nitrogen

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

    Solvent & Solubility
    In Vitro: 

    H2O : 25 mg/mL (57.63 mM; Need ultrasonic)

    DMSO : 12.5 mg/mL (28.81 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.3051 mL 11.5255 mL 23.0510 mL
    5 mM 0.4610 mL 2.3051 mL 4.6102 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (4.79 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (4.79 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 5 mg/mL (11.53 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation

    Purity: 99.85%

    SDS (644 KB)

    COA (255 KB) HNMR (276 KB) LCMS (94 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO / H2O 1 mM 2.3051 mL 11.5255 mL 23.0510 mL 57.6276 mL
    5 mM 0.4610 mL 2.3051 mL 4.6102 mL 11.5255 mL
    10 mM 0.2305 mL 1.1526 mL 2.3051 mL 5.7628 mL
    15 mM 0.1537 mL 0.7684 mL 1.5367 mL 3.8418 mL
    20 mM 0.1153 mL 0.5763 mL 1.1526 mL 2.8814 mL
    25 mM 0.0922 mL 0.4610 mL 0.9220 mL 2.3051 mL
    H2O 30 mM 0.0768 mL 0.3842 mL 0.7684 mL 1.9209 mL
    40 mM 0.0576 mL 0.2881 mL 0.5763 mL 1.4407 mL
    50 mM 0.0461 mL 0.2305 mL 0.4610 mL 1.1526 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Indomethacin sodium hydrate Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Indomethacin sodium74252-25-8Indometacin sodiumCOXBacterialInfluenza VirusAntibioticCyclooxygenaseanti-infectiveanticancerinflammationCOX-1COX-2Inhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Indomethacin sodium hydrate
    Cat. No.:
    HY-14397A
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (644 KB) Français - FR (644 KB) Deutsch - DE (644 KB) Norwegian - NO (644 KB) Español - ES (644 KB) Swedish - SV (644 KB) Italian - IT (644 KB) Korean - KR (644 KB) Portuguese - PT (644 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.